Piper Sandler Initiates Coverage On Bicara Therapeutics with Overweight Rating, Announces Price Target of $36
Benzinga Newsdesk 1 year ago
NewsPrice TargetInitiationAnalyst Ratings
Piper Sandler analyst Kelsey Goodwin initiates coverage on Bicara Therapeutics (NASDAQ:BCAX) with a Overweight rating and announces Price Target of $36.
Piper Sandler analyst Kelsey Goodwin initiates coverage on Bicara Therapeutics (NASDAQ:BCAX) with a Overweight rating and announces Price Target of $36.